Identity
What is the molecule or mixture? Is the name specific, or is it a marketing umbrella such as “Lipo-C”?
RESEARCH STANDARDS
Mechanism is not outcome. A study is not approval.
Cybertide’s editorial standard separates biological plausibility, preclinical evidence, human trials, approved labeling, formulation quality, and marketing claims.
Evidence tier
Cell culture, animal models, small human studies, pivotal trials, and approved indications are not interchangeable.
Route & formulation
Topical evidence does not validate injection. An approved drug is not automatically equivalent to a compounded or research-market vial.
Claim boundary
We say what is being studied, what the strongest evidence shows, and what cannot responsibly be concluded.
SELECTED PRIMARY SOURCES
↗FDA: safety risks for certain compounded bulk substances
↗BPC-157, TB-500 fragment, MOTS-c, GHK-Cu, ipamorelin, Semax, and Selank
FDA: accelerated approval of Forzinity
↗Elamipretide / SS-31 for a specific Barth syndrome population
FDA label: Vyleesi
↗Bremelanotide / PT-141 approved indication and limitations
FDA label: Egrifta SV
↗Tesamorelin approved indication and limitations
ClinicalTrials.gov: TRIUMPH-1
↗Retatrutide Phase 3 study record
ClinicalTrials.gov: ARA-290
↗Cibinetide study in sarcoidosis-associated small-fiber neuropathy
FDA: sterile compounding reminder
↗Reported adverse events associated with injectable NAD+ products
FDA label: Carnitor injection
Levocarnitine approved deficiency indications and warnings
EXPLORE THE WORK